Influenza A virus H7N9 vaccine - Hualan Biological Bacterin

Drug Profile

Influenza A virus H7N9 vaccine - Hualan Biological Bacterin

Latest Information Update: 28 Jul 2017

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Hualan Biological Bacterin
  • Class Influenza A vaccines; Influenza A virus H7N9 vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase I Influenza A virus H7N9 subtype

Most Recent Events

  • 23 Mar 2017 Hualan Biological Bacterin completes a phase I trial in Influenza-A virus H7N9 subtype in China (NCT03196661)
  • 06 Nov 2015 Phase-I clinical trials in Influenza-A virus H7N9 subtype (Prevention) in China (IM) (NCT03196661)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top